YORK, Pa. — Unilife Corp. has entered a deal with Hikma to launch 20 generic injectable drugs using Unilife's pre-filled syringe technology, the two companies said Wednesday.
Under the 15-year agreement, Unilife will supply Hikma with its platform, including the Unifill syringe and the Unifill Nexus. Hikma has selected an initial list of 20 generic injectable products that it will include in the deal.
Under the deal, Hikma will pay Unilife $40 million, including $5 million upfront, $15 million in 2014 and $20 million in 2015.
"This agreement supports our strategy of developing higher-value products, and we are extremely pleased to be partnering with Unilife to develop our generic injectables capabilities," Hikma CEO Said Darwazah said. "We look forward to leveraging Unilife's innovative platform of Unifill syringes to differentiate our injectable products and to increase our market share."